Does promethazine possess antispasmodic properties?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Promethazine Does Not Possess Antispasmodic Properties

Promethazine is a phenothiazine derivative with antihistamine, sedative, antiemetic, and anticholinergic effects, but antispasmodic activity is not among its recognized pharmacologic properties. 1, 2, 3

Established Pharmacologic Properties

The FDA-approved drug label and major gastroenterology guidelines consistently describe promethazine's mechanism of action without mentioning antispasmodic effects 3:

  • H1 receptor antagonism - Blocks histamine at H1 receptors 2, 3
  • Dopamine receptor blockade - Acts on postsynaptic dopaminergic receptors in the brain 2
  • Anticholinergic effects - Produces antimuscarinic activity, which theoretically could reduce smooth muscle tone through a different mechanism than direct antispasmodic action 1, 3
  • Sedative properties - Provides central nervous system depression 1, 3
  • Antiemetic action - Effective for nausea and vomiting 4, 5

Anticholinergic vs. Antispasmodic Distinction

While promethazine has anticholinergic properties 1, 2, 3, this should not be confused with direct antispasmodic activity:

  • Anticholinergic effects include dry mouth, urinary retention, and blurred vision - these are side effects rather than therapeutic antispasmodic actions 3
  • The FDA label specifically warns about using promethazine cautiously in patients with "stenosing peptic ulcer, pyloroduodenal obstruction, and bladder-neck obstruction" 3, suggesting its anticholinergic effects could worsen rather than relieve spasm-related conditions
  • True antispasmodics (like dicyclomine or hyoscyamine) directly relax smooth muscle through different mechanisms

Clinical Context

In gastroenterology guidelines, promethazine is discussed exclusively as an adjunct sedative and antiemetic for endoscopic procedures 1, 2, not for treating gastrointestinal spasm:

  • Typical dosing is 12.5-25 mg IV (infused slowly at ≤25 mg/min) as an adjuvant to narcotics and benzodiazepines 1
  • Used to reduce requirements for standard sedation agents 1, 2
  • No mention of antispasmodic indications in any reviewed guidelines [@1-@12@]

Important Safety Considerations

The anticholinergic properties of promethazine can cause significant adverse effects [@14@]:

  • Should be used with caution in patients with narrow-angle glaucoma, prostatic hypertrophy, and bladder-neck obstruction [@14@]
  • Can cause serious tissue injury with extravasation or inadvertent intra-arterial injection [@1@, @8@, @15@]
  • Recent safety organizations have called for removal of injectable promethazine from formularies due to limb-threatening complications [@15@, @21

References

Guideline

aga institute review of endoscopic sedation.

Gastroenterology, 2007

Guideline

nccn guidelines insights: antiemesis, version 2.2017.

Journal of the National Comprehensive Cancer Network : JNCCN, 2017

Guideline

the management of nausea and vomiting in pregnancy and hyperemesis gravidarum (green-top guideline no. 69).

BJOG : an international journal of obstetrics and gynaecology, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.